Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

t on Form 10-K for the year ended December 31, 2011 and Form 10-Q for the quarter ended September 30, 2012. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

 NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited) Three Months EndedDecember 31, Year EndedDecember 31, 2012201120122011Revenues:Sponsored research and development

$
3,959

$
,873

$
8,897

$
,462Milestones and license fees

7,988

9,237

34,243

66,951Total revenues

21,947

11,110

53,140

77,413Operating expenses:Research and development

9,097

8,002

37,163

30,951General and administrative

3,311

2,668

13,437

12,458Cease-use expense

957

(7)

1,092

82Total operating expenses

13,365

10,663

51,692

43,491Income from operations

8,582

447

1,448

33,922Other income:Gain on sale/disposal of assets

7

58

32

242Deferred gain on real estate

766

744

3,042

2,953Investment income, net

130

77

489

418Other income, net

5

5

14

36Total other income

908

884

3,577

3,649Net income

$
9,490

$
,331

$
5,025

$
37,571Net income per common share:Basic

$
.14

$
.02

$
.08

$
.68Diluted

$
.14

$
.02

$
.08

$
.67Shares used in the calculation of net income per common share:Basic

66,406

55,259

65,619

55,176Diluted

67,720

56,461

66
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... SAN DIEGO , June 30, 2015 /PRNewswire/ ... Continuing Education in Biosciences (CCE/Bio) and UC San ... microbial fermentation, to be held Aug.  12 – ... agenda ).  This three-day workshop provides an intense ... in industrial biotechnology, and is well-suited to biologists, ...
(Date:6/30/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... on the development of autologous cell therapies, announced today ... clinical trial of RCT-01, being tested for the ... enrolled and their tissue biopsy sent for processing ... of non-bulbar dermal sheath (NBDS) cells isolated from ...
(Date:6/30/2015)... Edwardsville, IL (PRWEB) , ... June 30, 2015 ... ... resigned effective August 14. She has accepted the position of vice president of ... on August 17. , “I greatly appreciated the opportunity to lead SIUE ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by filmmakers, the ... dynamic collection of legal medical cannabis stories ever assembled. , Cannavoices profiles ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... Feb. 26 One of,Brazil,s leading distributors of pharmaceutical products, ... has just announced its results for the fourth quarter of,2007 ... PERIOD, -- Profarma,s market share breaks record and reaches ... above the share reached in the 3Q07 and 3.2 ...
... 8: ,Venous Thromboembolism and Mortality Associated with Recombinant ... the Treatment of Cancer-Associated Anemia, BRIDGEWATER, N.J., Feb. ... study published in the February 27, 2008 issue of ... et al, do,not provide an accurate reflection of the ...
... ALTO, Calif., Feb. 26 CV Therapeutics,Inc. (Nasdaq: CVTX ... year ended December 31, 2007., For the quarter ended ... million, or $0.57 per share. This compares to a net ... quarter in 2006 and $34.2,million, or $0.58 per share, for ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8
(Date:6/15/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces that its leading payment security technology, ... Digital Experience! @ NYC June 18th. Digital Experience! ... innovation in technology to over 300 of the top media ... Metropolitan Pavilion in New York City ...
(Date:6/11/2015)... RESTON, Va. , June 11, 2015 /PRNewswire/ ... authentication technology, announced today that its IdentityX Mobile ... FIDO (Fast IDentity Online) Alliance is an industry ... with open standards for simpler, stronger authentication.  In ... services must pass a rigorous series of tests ...
(Date:6/9/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, will be providing demonstrations of its ... 2015 Drug Information Association (DIA) Annual Meeting in ... presentations will include previews of many exciting new enhancements ... iMedNet 2015 Feature 1 Release. ...
Breaking Biology News(10 mins):Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... risk of death among injection drug users living with ... (ART), according to a new study involving Simon Fraser ... journal, PLoS One , examines the impact of ... users. Food insecurity is defined by the United Nations, ...
... sensitive ears of a parasitic fly for inspiration, a ... microphone that achieves better acoustical performance than what is ... their results at the 21st International Congress on Acoustics, ... Distinguished Professor of Mechanical Engineering at Binghamton University, studies ...
... at the MRC Laboratory of Molecular Biology in the United ... found in cells that when mutated can lead to a ... in The EMBO Journal , define the position of ... explain how these alterations may affect the stability and function ...
Cached Biology News:Food insecurity linked to HIV-treated drug users' deaths 2Researchers design sensitive new microphone modeled on fly ear 2How disease mutations affect the Parkin protein 2
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Oct 2 Immunogen: Full length human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: